{'fraction_non_alphanumeric': 0.020072992700729927, 'fraction_numerical': 0.010948905109489052, 'mean_word_length': 4.625641025641026, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment of neonatal candidiasis with liposomal amphotericin B.

3. To claim a 100% response rate in the assessable cases fails to consider the fact that the patients who died or were otherwise non-evaluable could have had persisting fungal infections and in fact, may have been treatment failures. This is the rationale behind an intent-to-treat analysis, where all patients who receive atleast one dose of study drug treatment must be included in the efficacy analysis. Viewed in this way according to the results presented in Table I of the article, 13 of 23 patients treated had favourable outcomes, a response rate of 56.5%. 4. It should also be noted that all patients in this report had infections with Candida albicans. The other reports referenced included cases of non-albicans species of Candida as well, which are known to be more difficult to treat and many require longer courses of treatment. Thus, the response rate of treatment as well as the total doses of Amphotericin B needed to treat in this paper are not appropriately comparable to those reported in the references cited.